Product Information
Registration Status: ActiveSIN13037P
NIASPAN 500MG EXTENDED-RELEASE TABLET is approved to be sold in Singapore with effective from 2004-11-23. It is marketed by ABBOTT LABORATORIES (SINGAPORE ) PTE LTD, with the registration number of SIN13037P.
This product contains Nicotinic Acid 500mg in the form of TABLET, DELAYED-RELEASE. It is approved for ORAL use.
This product is manufactured by AbbVie LTD in PUERTO RICO.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem]
Indication
For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Mechanism of Action
Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.
Pharmacokinetics
- Absorption
- Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.
- Distribution
- Metabolism
- Hepatic
- Elimination
Toxicity
Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD50 7000 mg/kg (Rat)
Active Ingredient/Synonyms
3-carboxypyridine | 3-Pyridinecarboxylic acid | 3-Pyridylcarboxylic acid | Acide Nicotinique | Acido nicotinico | Acidum Nicotinicum | Anti-pellagra vitamin | beta-Pyridinecarboxylic acid | M-Pyridinecarboxylic Acid | Niacin | Nicotinic Acid | Nikotinsaeure | P.P. factor | Pellagra preventive factor | PP Factor | Pyridine-beta-carboxylic acid | pyridine-β-carboxylic acid | Vitamin B3 | β-pyridinecarboxylic acid | Niacin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.